Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

1.

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.

Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, Sadrolhefazi B, Gu Y, Liu D, Pilz K, Chu Q.

Clin Lung Cancer. 2015 Jun 2. pii: S1525-7304(15)00142-4. doi: 10.1016/j.cllc.2015.05.010. [Epub ahead of print]

PMID:
26100229
2.

Ageing and visual spatiotemporal processing.

Pilz KS, Kunchulia M, Parkosadze K, Herzog MH.

Exp Brain Res. 2015 Aug;233(8):2441-8. doi: 10.1007/s00221-015-4314-9. Epub 2015 May 20.

PMID:
25990820
3.

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.

Awada A, Dumez H, Aftimos PG, Costermans J, Bartholomeus S, Forceville K, Berghmans T, Meeus MA, Cescutti J, Munzert G, Pilz K, Liu D, Schöffski P.

Invest New Drugs. 2015 Jun;33(3):611-20. doi: 10.1007/s10637-015-0223-9. Epub 2015 Mar 22.

4.

Small effects of smoking on visual spatiotemporal processing.

Kunchulia M, Pilz KS, Herzog MH.

Sci Rep. 2014 Dec 4;4:7316. doi: 10.1038/srep07316.

5.

Biological knee reconstruction for combined malalignment, meniscal deficiency, and articular cartilage disease.

Harris JD, Hussey K, Wilson H, Pilz K, Gupta AK, Gomoll A, Cole BJ.

Arthroscopy. 2015 Feb;31(2):275-82. doi: 10.1016/j.arthro.2014.08.012. Epub 2014 Oct 16.

PMID:
25442661
6.

Laser-induced breakdown spectroscopy for 24/7 automatic liquid slag analysis at a steel works.

Sturm V, Fleige R, de Kanter M, Leitner R, Pilz K, Fischer D, Hubmer G, Noll R.

Anal Chem. 2014 Oct 7;86(19):9687-92. doi: 10.1021/ac5022425. Epub 2014 Sep 9.

PMID:
25203225
7.

An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, Modi S, Lee P, Ernstoff MS, Su WC, Spira A, Pilz K, Vinisko R, Schloss C, Fritsch H, Zhao C, Carducci MA.

Cancer. 2014 Apr 1;120(7):976-82. doi: 10.1002/cncr.28519. Epub 2013 Dec 11.

8.

Long-lasting visual integration of form, motion, and color as revealed by visual masking.

Pilz KS, Zimmermann C, Scholz J, Herzog MH.

J Vis. 2013 Aug 20;13(10). pii: 12. doi: 10.1167/13.10.12.

PMID:
23962737
9.

How alcohol intake affects visual temporal processing.

Kunchulia M, Pilz KS, Herzog MH.

Vision Res. 2012 Aug 1;66:11-6. doi: 10.1016/j.visres.2012.06.010. Epub 2012 Jun 23.

10.

What the human brain likes about facial motion.

Schultz J, Brockhaus M, Bülthoff HH, Pilz KS.

Cereb Cortex. 2013 May;23(5):1167-78. doi: 10.1093/cercor/bhs106. Epub 2012 Apr 24.

11.

How prevalent is object-based attention?

Pilz KS, Roggeveen AB, Creighton SE, Bennett PJ, Sekuler AB.

PLoS One. 2012;7(2):e30693. doi: 10.1371/journal.pone.0030693. Epub 2012 Feb 13.

12.

Age-related changes in matching novel objects across viewpoints.

Pilz KS, Konar Y, Vuong QC, Bennett PJ, Sekuler AB.

Vision Res. 2011 Sep 1;51(17):1958-65. doi: 10.1016/j.visres.2011.07.009. Epub 2011 Jul 19.

13.

Spatiotemporal properties of apparent motion perception and aging.

Roudaia E, Bennett PJ, Sekuler AB, Pilz KS.

J Vis. 2010 Dec 3;10(14):5. doi: 10.1167/10.14.5.

PMID:
21131565
14.

Walk this way: approaching bodies can influence the processing of faces.

Pilz KS, Vuong QC, Bülthoff HH, Thornton IM.

Cognition. 2011 Jan;118(1):17-31. doi: 10.1016/j.cognition.2010.09.004. Epub 2010 Nov 2.

PMID:
21047624
15.

Effects of aging on biological motion discrimination.

Pilz KS, Bennett PJ, Sekuler AB.

Vision Res. 2010 Jan;50(2):211-9. doi: 10.1016/j.visres.2009.11.014. Epub 2009 Nov 23.

16.

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U; FLEX Study Team.

Lancet. 2009 May 2;373(9674):1525-31. doi: 10.1016/S0140-6736(09)60569-9.

PMID:
19410716
17.

Natural facial motion enhances cortical responses to faces.

Schultz J, Pilz KS.

Exp Brain Res. 2009 Apr;194(3):465-75. doi: 10.1007/s00221-009-1721-9. Epub 2009 Feb 11.

18.

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M.

Ann Oncol. 2008 Feb;19(2):362-9. Epub 2007 Oct 17.

19.

No sex difference in yolk steroid concentrations of avian eggs at laying.

Pilz KM, Adkins-Regan E, Schwabl H.

Biol Lett. 2005 Sep 22;1(3):318-21.

20.

Modulation of visual stimulus discrimination by sustained focal attention: an MEG study.

Pilz KS, Braun C, Altpeter E, Mackeben M, Trauzettel-Klosinski S.

Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1225-9.

PMID:
16505062
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk